Your Pursuit.Our Mission.

Creating novel solutions to treat patients with chronic metabolic and liver diseases.

Pipeline

Our focus in the clinic is on advancing our lead candidate, berberine ursodeoxycholate (HTD1801), in chronic metabolic diseases and liver diseases. Based on its dual mechanism of action we are particularly focused on diseases driven by insulin resistance and chronic inflammation. In addition to our lead candidate, we have a growing discovery portfolio.

Man peering through microscope
Obesity
MASH
T2DM
Hyperlipidemia
Metabolic
Syndrome
Insulin Resistance
&
Chronic Inflammation

Our Approach

HighTide’s mission is to identify the unmet needs in these inter-related chronic metabolic and liver diseases and translate those needs into new therapeutic solutions.